Abdakibart

阿卜达奇拜单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameAbdakibart
Drug Alias NameIL-1β antibody - Eli LillyLY-2189102FL-101AVTX-009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-1 beta inhibitorsImmunosuppressants
TargetsInterleukin-1 beta
Therapy Area/IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 2Arthritis, Rheumatoid +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesAvalo Therapeutics IncFlame Biosciences Inc
Inactive CompaniesEli Lilly And Company
Active IndicationsAutoimmune DiseasesHidradenitis Suppurativa
Inactive IndicationsDiabetes Mellitus, Type 2Arthritis, RheumatoidUrinary Bladder Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG